Mikhail Martchenko Shilman

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8415132/mikhail-martchenko-shilman-publications-by-year.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22 papers	413 citations	11 h-index	20 g-index
22 ext. papers	482 ext. citations	5.7 avg, IF	3.41 L-index

#	Paper	IF	Citations
22	Activity of Repurposed Amodiaquine as a Host-Targeting Therapy for the Treatment of Anthrax. *ACS Infectious Diseases*, **2021**, 7, 2176-2191	5.5	
21	Y Chromosome Genes Affect Male Sensitivity to Microbial Infections. *Insects*, **2021**, 12,	2.8	1
20	Identification of glucocorticoid receptor in Drosophila melanogaster. *BMC Microbiology*, **2020**, 20, 161	4.5	4
19	Identification of clinically approved small molecules that inhibit growth and affect transcript levels of developmentally regulated genes in the African trypanosome. *PLoS Neglected Tropical Diseases*, **2020**, 14, e0007790	4.8	1
18	Identification of Bithionol, Dichlorophen, and Miconazole as Antibacterial Agents against. *ACS Omega*, **2020**, 5, 23951-23959	3.9	1
17	Antifungal Drug Repurposing. *Antibiotics*, **2020**, 9,	4.9	13
16	Anthrax toxin component, Protective Antigen, protects insects from bacterial infections. *PLoS Pathogens*, **2020**, 16, e1008836	7.6	2
15	Repurposing Clinically Approved Drugs for the Treatment of , a Surrogate for. *ACS Omega*, **2020**, 5, 21929-21939	3.9	2
14	Investigation of the immunogenicity of Zika glycan loop. *Virology Journal*, **2020**, 17, 43	6.1	3
13	Characterization of Novel Piperidine-Based Inhibitor of Cathepsin B-Dependent Bacterial Toxins and Viruses. *ACS Infectious Diseases*, **2018**, 4, 1235-1245	5.5	4
12	Role of a Small Molecule in the Modulation of Cell Death Signal Transduction Pathways. *ACS Infectious Diseases*, **2018**, 4, 1746-1754	5.5	6
11	Bithionol blocks pathogenicity of bacterial toxins, ricin, and Zika virus. *Scientific Reports*, **2016**, 6, 34475	4.9	20
10	Cross-inhibition of pathogenic agents and the host proteins they exploit. *Scientific Reports*, **2016**, 6, 34846	4.9	4
9	Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen-The first step toward a rationally designed anthrax vaccine. *Vaccine*, **2016**, 34, 13-9	4.1	19
8	Presentation of peptides from Bacillus anthracis protective antigen on Tobacco Mosaic Virus as an epitope targeted anthrax vaccine. *Vaccine*, **2015**, 33, 6745-51	4.1	14
7	Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting. *Scientific Reports*, **2015**, 5, 13476	4.9	34
6	Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans. *Annals of Clinical Microbiology and Antimicrobials*, **2015**, 14, 32	6.2	31

5	Calpain-dependent cytoskeletal rearrangement exploited for anthrax toxin endocytosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E4007-15	11.5	24
4	Human genetic variation altering anthrax toxin sensitivity. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 2972-7	11.5	18
3	Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 15583-8	11.5	53
2	Transcriptional rewiring of fungal galactose-metabolism circuitry. *Current Biology*, **2007**, 17, 1007-13	6.3	138
1	Transcriptional activation domains of the Candida albicans Gcn4p and Gal4p homologs. *Eukaryotic Cell*, **2007**, 6, 291-301		21